Paclitaxel and mortality in patients with claudication and de novo femoropopliteal lesions: a historical cohort study.

There was no excess mortality in patients with claudication and de novo femoropopliteal lesions treated with paclitaxel coated devices at 1, 2 and 5 years of follow-up in this cohort. The current study suggests that additional prospective randomized studies properly powered to study mortality are necessary.